Business Pipeline How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup BioPharma DiveCohen says he looked at around two dozen companies since Acorda wound down.PipelineNeuroscienceRead full story pharminent March 24, 2026 (Last updated: March 24, 2026) BioPharma Dive Cohen says he looked at around two dozen companies since Acorda wound down. PipelineNeuroscience Read full story Post navigation Previous: Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study resultsNext: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
